The Chalcogen, X, Is In A -c(=x)- Group Patents (Class 546/340)
-
Patent number: 7998973Abstract: A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per week. In some embodiments of the invention, the tivozanib is administered on a repeating schedule of one dose per day for three weeks, followed by one week without tivozanib administration. The disclosed method is particularly suitable for treatment of renal cell carcinoma.Type: GrantFiled: August 13, 2010Date of Patent: August 16, 2011Assignee: AVEO Pharmaceuticals, Inc.Inventors: Pankaj Bhargava, W. Brooke Esteves, John L. Ryan
-
Publication number: 20110190325Abstract: Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).Type: ApplicationFiled: August 14, 2009Publication date: August 4, 2011Inventors: Gerald B. Hammond, Jose C. Aponte, Robert H. Gilman, Michel Henri Auguste Sauvain, Abraham Caisberg
-
Publication number: 20110143197Abstract: An electrode active material for a power storage device of the invention includes an organic compound having, in the molecule, a plurality of electrode reaction sites and a linker site. The electrode reaction sites are residues of a 9,10-phenanthrenequinone compound that contributes to an electrochemical redox reaction. The linker site is disposed between the plurality of electrode reaction sites, does not contain any ketone group, and does not contribute to the electrochemical redox reaction. The electrode active material for a power storage device of the present invention is inhibited from being dissolved in an electrolyte and has a high energy density. By using the electrode active material, it is possible to obtain a power storage device having a high energy density and excellent charge/discharge cycle characteristics.Type: ApplicationFiled: February 16, 2009Publication date: June 16, 2011Inventors: Yu Ohtsuka, Nobuhiko Hojo, Junichi Yoshida, Toshiki Nokami
-
Patent number: 7960369Abstract: The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.Type: GrantFiled: November 6, 2003Date of Patent: June 14, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Kohji Fukatsu, Shinobu Sasaki, Shuji Hinuma, Yasuaki Ito, Nobuhiro Suzuki, Masataka Harada, Tsuneo Yasuma
-
Publication number: 20110112151Abstract: There is provided a compound of formula R1—CO—X—Y—Z—R2 wherein X and Z are each optional groups that are, independently, saturated or unsaturated carbon chains having a length of 1 to 3 carbons; Y is SO, S, SO2, CH?CH, CH2CH2 or O; R1 is wherein denotes the point of attachment; R2 is a heteroaryl group comprising an optionally substituted 5 or 6 membered ring, which ring contains only carbon and at least one nitrogen, or contains only carbon, and at least two nitrogens and at least one sulfur; and wherein (i) when R1 is and —CO—X—Y—Z— is CO—CH2—SO, CO—CH2—S, or CO—CH2—SO2, R2 is other than and; (ii) when R1 is and —CO—X—Y—Z— is —CO—CH2—O—, R2 is other thanType: ApplicationFiled: February 25, 2009Publication date: May 12, 2011Inventors: Nigel Vicker, Xiangdong Su, Fabienne Pradaux-Caggiano, Barry Victor Lioyd Potter
-
Patent number: 7935688Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: GrantFiled: June 9, 2006Date of Patent: May 3, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tadakatsu Takahashi, Yoshiyuki Ono, Hirotaka Kashiwagi, Tsuyoshi Haneishi, Kazuki Shimizu
-
Patent number: 7935827Abstract: The present invention relates to new optically active heteroaromatic ?-hydroxy esters useful in the synthesis of epothilone derivatives, to certain compounds used to produce these intermediates, as well as to processes for their production.Type: GrantFiled: December 18, 2008Date of Patent: May 3, 2011Assignee: Bayer Schering Pharma AGInventors: Johannes Platzek, Ludwig Zorn, Bernd Buchmann, Werner Skuballa, Orlin Petrov
-
Patent number: 7935848Abstract: Cooling compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl, C1-C3 alkoxy, phenyl, C1-C3 alkylphenyl, C1-C3 alkoxyphenyl, thienyl, pyridyl, furyl, and indoyl; R2 is selected from the group consisting of hydrogen and hydroxyl, or R2 forms together with the carbon atom to which it is attached a carbonyl group; and R3 is selected from the group consisting of 2,4-dimethylpent-3-yl, 2,3,4-trimethylpent-3-yl, adamantyl and 2-isopropyl-5-methyl-cyclohexyl-1-yl; and, product compositions comprising them.Type: GrantFiled: May 14, 2008Date of Patent: May 3, 2011Assignee: Givaudan S.A.Inventors: Stefan Michael Furrer, David Max Dastrup, Thomas Scott McCluskey
-
Publication number: 20110077407Abstract: A process for the preparation of functional molecules using the thiol-ene coupling reaction and a process for the preparation of protected functional thiols, specifically thioesters is provided. The methods may be used to make functional polymers and other molecules. The method of making a functionalized polymer using a thiol-ene reaction comprises: providing a functionalized thioester having the following formula: wherein R is a functional group and COR? is a protecting group; cleaving the functionalized thioester, forming a functional thiol and an acyl group; providing a polymer having a pendant vinyl group; and reacting the polymer with the functional thiol whereby a functionalized polymer is formed, wherein the functional thiol is not isolated prior to reacting with the polymer.Type: ApplicationFiled: December 6, 2010Publication date: March 31, 2011Inventors: Ralph L. David, Julia A. Kornfield
-
Publication number: 20110021576Abstract: A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.Type: ApplicationFiled: October 2, 2010Publication date: January 27, 2011Applicant: Cadila Healthcare LimitedInventors: Bipin Pandey, Vidya Bhushan Lohray, Braj Bhushan Lohray
-
Patent number: 7872029Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: August 22, 2008Date of Patent: January 18, 2011Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Publication number: 20100297077Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.Type: ApplicationFiled: October 3, 2008Publication date: November 25, 2010Applicant: BIONOMICS LIMITEDInventors: Bernard Luke Flynn, Jonathan Bayldon Baell, Jason Hugh Chaplin, Girmit Singh Gill, Damian Wojciech Grobelny, Andrew John Harvey, Jorgen Alvar Mould, Dharam Paul
-
Publication number: 20100292472Abstract: The present invention can provide a novel medicament that is safe, cheap and effective for prophylaxis or therapy of apicomplexan infections, such as malaria and toxoplasmosis by applying a plant growth regulator selected from the group consisting of gibberellin inhibitors, cytokinins and ethylene inhibitors to the prophylactic or therapeutic treatment of such apicomplexan infections.Type: ApplicationFiled: January 22, 2009Publication date: November 18, 2010Inventors: Tomoko Toyama, Kisaburo Nagamune, Toshihiro Horii, Kazuyuki Tanabe
-
Patent number: 7816523Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: GrantFiled: August 28, 2009Date of Patent: October 19, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang
-
Patent number: 7816535Abstract: The invention relates to compounds of structural formula (Ia): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, X4, X6, X10, R1, Y, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.Type: GrantFiled: January 25, 2007Date of Patent: October 19, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Gary Bohnert, Shoujun Chen, Yu Xie
-
Publication number: 20100261758Abstract: Compounds of Formula (I) wherein R1 is aryl, cyclohexyl or heterocyclyl, or (C1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R2 is defined heterocyclyl, R3 is alkyl, aryl, cyclohexyl or heterocyclyl, or (C1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R4 is H or alkyl, or R3 and R4 together with the carbon atom to which they are attached are cycloalkyl fused with aryl, and their use as pharmaceuticals.Type: ApplicationFiled: March 28, 2007Publication date: October 14, 2010Applicant: NOVARTIS AGInventors: Luca Arista, Klemens Hogenauer, Niko Schmiedeberg, Gudrun Werner, Herbert Jaksche
-
Publication number: 20100249165Abstract: This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions.Type: ApplicationFiled: June 3, 2008Publication date: September 30, 2010Applicants: University of Copenhagen, NeuroSearch A/SInventors: Ulrik Gether, Kenneth Madsen, Thor Seneca Thorsen, Dan Peters, Tino Dyhring, Lars Christian Rønn
-
Publication number: 20100240900Abstract: The carbon nanomaterials and methods relate to methods for causing carbon nanospheres to be readily dispersible in a material. The carbon nanospheres are rendered dispersible using a cationic surfactant. The surfactant includes one or more cationic group that can bond to the surface of the carbon nanospheres, without detrimentally affecting the unique properties of carbon nanospheres. The dispersible carbon nanospheres can be dried (i.e., solvent is driven off) while maintaining their dispersibility in solvents and other materials.Type: ApplicationFiled: March 23, 2009Publication date: September 23, 2010Applicant: HEADWATERS TECHNOLOGY INNOVATION, LLCInventors: Cheng Zhang, Gaurang Bhargava, Bing Zhou
-
Publication number: 20100216638Abstract: Bicyclic dione compounds of formula (I), and derivatives thereof, which are suitable for use as herbicides.Type: ApplicationFiled: May 27, 2008Publication date: August 26, 2010Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Christopher John Mathews, Matthew Brian Hoston, Alan John Dowling, James Nicholas Scutt, Mangala Govenkar, Lee Challinor
-
Publication number: 20100210653Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome proliferator-activated receptors (PPAR), in particular the PPAR? suptype.Type: ApplicationFiled: April 30, 2010Publication date: August 19, 2010Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Miroslav Havranek, Per Sauerberg, Ingrid Pettersson
-
Publication number: 20100197713Abstract: Cooling compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl, C1-C3 alkoxy, phenyl, C1-C3 alkylphenyl, C1-C3 alkoxyphenyl, thienyl, pyridyl, furyl, and indoyl; R2 is selected from the group consisting of hydrogen and hydroxyl, or R2 forms together with the carbon atom to which it is attached a carbonyl group; and R3 is selected from the group consisting of 2,4-dimethylpent-3-yl, 2,3,4-trimethylpent-3-yl, adamantly and 2-isopropyl-5-methyl-cyclohe?yl-1-yI; and, product compositions comprising them.Type: ApplicationFiled: May 14, 2008Publication date: August 5, 2010Applicant: GIVAUDAN SAInventors: Stefan Michael Furrer, David Max Dastrup, Thomas Scott McCluskey
-
Publication number: 20100184986Abstract: Organocatalysts, particularly proline sulfonamide organocatalysts, having a first general formula as follows are disclosed. Embodiments of a method for using these organocatalysts also are disclosed. The method comprises providing a disclosed organocatalyst, and performing a reaction, often an enantioselective or diastereoselective reaction, using the organocatalyst. Solely by way of example, disclosed catalysts can be used to perform aldol reactions, conjugate additions, Michael additions, Robinson annulations, Mannich reactions, ?-aminooxylations, ?-hydroxyaminations, ?-aminations and alkylation reactions. Certain of such reactions are intramolecular cyclizations used to form cyclic compounds, such as 5- or 6-membered rings, having one or more chiral centers. Disclosed organocatalysts generally are much more soluble in typical solvents used for organic synthesis than are known compounds.Type: ApplicationFiled: March 17, 2010Publication date: July 22, 2010Inventors: Rich Garrett Carter, Hua Yang
-
Publication number: 20100173774Abstract: Cyclohexanedione compounds, and derivatives thereof, which are substituted in 5-position, are suitable for use as herbicides.Type: ApplicationFiled: March 7, 2008Publication date: July 8, 2010Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Michel Muehlebach, William Lutz, Jean Wenger, John Finney, Christopher John Matthews, Delphine Fawke
-
Publication number: 20100130737Abstract: The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5- to 7-membered ring, V is a bond or the group represented by the formula —CR14?CR15— or —N?CR16— (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof.Type: ApplicationFiled: February 17, 2006Publication date: May 27, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Fumio Itoh, Eiji Kimura, Yumi Imai, Masaaki Mori, Yoshio Aramaki, Yasuhisa Kohara, Tsukasa Sugo, Yoji Hayase, Hiromi Kobayashi, Kazuhiro Ogi
-
Publication number: 20100121062Abstract: A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: R1—B-T ??(I); where R1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pKB of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.Type: ApplicationFiled: September 25, 2009Publication date: May 13, 2010Applicant: The Board of Trustees of the University of IllinoisInventors: Martin D. Burke, David M. Knapp, Eric P. Gillis
-
Publication number: 20100111888Abstract: Disclosed are compounds having the ability to modulate, namely to improve, enhance and or modify fragrance compositions due to their ability to inhibit cytochrome P450 enzymes, e.g. CYP2A13 and CYP2B6.Type: ApplicationFiled: March 20, 2008Publication date: May 6, 2010Applicant: GIVAUDAN SAInventors: Boris Schilling, Thierry Granier, Georg Frater, Andreas Hanhart
-
Publication number: 20100112545Abstract: Novel trans-1,2-diphenylethylene derivatives are synthesized which can be used to form nanoparticles-monomer-nanomolecule-receptor nanosensors. These trans-1,2-diphenyl-ethylene derivatives are soluble in both water and organic solvents, highly fluorescent and can be synthesized in high yields. The trans-1,2-diphenylethylene derivatives are bonded to a nanoparticle, a nanomolecule bonded to the derivative and a receptor bonded to the nanomolecule to form a nanosensor that can be used to detect chemical and biological agents.Type: ApplicationFiled: July 13, 2007Publication date: May 6, 2010Inventors: Subra Muralidharan, Chun Wang
-
Publication number: 20100048901Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.Type: ApplicationFiled: November 30, 2007Publication date: February 25, 2010Applicants: TOKYO INSTITUTE OF TECHNOLOGY, Kyoto UniversityInventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome
-
Publication number: 20100035908Abstract: The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent —CH— or N; or X3, X4 and X5 independently of each other represent —CH— or N, and Xi and X2 independently of each other represent C and form part of an additional 6-membered aromatic ring; R1 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, or alkylcarbonyl, all of which are optionally substituted; R2 and R3 independently represent hydrogen, —CH2—C(O)NR—R?, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, hydroxyalkyl, heterocycloalkenyl, alkylaryl, alkylalkoxycarbonyl, alkylcarbonyloxy, or alkoxyalkyl, all of which are optionally substituted; R11 represents hydrogen, halogen, cyano, amino, alkoxy or alkylamino, X1-X5 represent —CH— or N, including N-oxides, enantiomers and diastereomers; and pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: ApplicationFiled: December 21, 2007Publication date: February 11, 2010Applicant: Leo PharmaInventors: Jakob Felding, Simon Feldbæk Nielsen
-
Patent number: 7629472Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2 are as defined above with a compound represented by the general formula: wherein R3, R4 and R5 are as defined above, and X is a halogen atom.Type: GrantFiled: June 14, 2007Date of Patent: December 8, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Toru Yamano, Naohiro Taya, Akio Ojida
-
Publication number: 20090298893Abstract: Addition salts of 2,4?-dimethyl-3-piperidinopropiophenone (tolperisone) are described, wherein the salt is formed with an acid R—COOH and wherein R is the organic group of a physiologically compatible organic acid. Described also are processes for the preparation of these addition salts, the use thereof for pharmaceutical preparations and pharmaceuticals containing these addition salts.Type: ApplicationFiled: March 21, 2006Publication date: December 3, 2009Inventors: Rudolf-Giesbert Alken, Frank Schneider
-
Patent number: 7626035Abstract: The present invention relates to new optically active heteroaromatic ?-hydroxy esters useful in the synthesis of epothilone derivatives, to certain compounds used to produce these intermediates, as well as to processes for their production.Type: GrantFiled: January 3, 2005Date of Patent: December 1, 2009Assignee: Bayer Schering Pharma AGInventors: Johannes Platzek, Ludwig Zorn, Bernd Buchmann, Werner Skuballa, Orlin Petrov
-
Publication number: 20090275575Abstract: Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be used to treat a normal proliferative state of a malignant tumor by killing the actively proliferating cells.Type: ApplicationFiled: September 21, 2007Publication date: November 5, 2009Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Nam-Song Choi, Young-Mi Kim, Young-Hoon Kim, Jae-Kwang Lee, In-Taek Lim, Ho-Jin Choi, Hyun-Mo Yang, Seung-Kee Moon, Soo-Jin Kim, Hyun-Jung Yu, Jae-Su Shin, Young-Min Kwon, Sung-Sook Lee, Soon-Kil Ahn
-
Patent number: 7598423Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: GrantFiled: November 15, 2005Date of Patent: October 6, 2009Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
-
Patent number: 7553970Abstract: The invention relates to a process for preparing enantiomer-enriched 3-heteroaryl-3-hydroxypropanoic acid derivatives and 3-heteroaryl-1-aminopropan-3-ols, and to their use.Type: GrantFiled: September 24, 2003Date of Patent: June 30, 2009Assignee: Lanxess Deutschland GmbHInventors: Frank Berendes, Markus Eckert, Nils Brinkmann, Claus Dreisbach, Ruth Meissner, Rainhard Koch
-
Patent number: 7550475Abstract: The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.Type: GrantFiled: September 6, 2006Date of Patent: June 23, 2009Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Tatsuzo Ukita, Yoshihiro Terakawa, Kazuteru Wada, Aya Nakata, Atsuko Sakai, Koji Ogawa
-
Patent number: 7550476Abstract: The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.Type: GrantFiled: September 6, 2006Date of Patent: June 23, 2009Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Tatsuzo Ukita, Yoshihiro Terakawa, Kazuteru Wada, Aya Nakata, Atsuko Sakai, Koji Ogawa
-
Publication number: 20090149510Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.Type: ApplicationFiled: July 7, 2008Publication date: June 11, 2009Inventor: David G. Hangauer, JR.
-
Publication number: 20090136431Abstract: The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I) as described above.Type: ApplicationFiled: November 6, 2006Publication date: May 28, 2009Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Akella S.S.V. Srinivas, Urkalan K. Balan, Narayana S. Punthalir, Rama S. Velmurugan, Sriram Rajagopal, Gaddam O. Reddy, Virendra Kachhadia
-
Patent number: 7531695Abstract: The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene expression. They exert their activity by interfering with certain cellular signal transduction cascades. The compounds of the invention are thus also useful for regulating cell differentiation and cell cycle processes that are controlled or regulated by various hormones or cytokines. In particular, the invention relates to compounds that induce apoptosis of cancer cells and therefore may be used for the treatment or prevention of cancer, including advanced cancers and pre-cancerous cells. The invention also discloses pharmaceutical compositions and methods of treatment of disease in mammals.Type: GrantFiled: June 3, 2004Date of Patent: May 12, 2009Assignee: Auspex Pharmaceutical, IncInventors: Borcherng Hong, Sepehr Sarshar, Bruno Tse
-
Publication number: 20090048220Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.Type: ApplicationFiled: August 8, 2008Publication date: February 19, 2009Applicant: Chiesi Farmaceutici S.p.A.Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
-
Publication number: 20090018167Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: ApplicationFiled: August 22, 2008Publication date: January 15, 2009Applicants: J. Phillip Bowen, Emory UniversityInventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Publication number: 20080318779Abstract: Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired.Type: ApplicationFiled: August 10, 2005Publication date: December 25, 2008Applicant: ISHIHARA SANGYO KAISHA LTDInventors: Yuji Nakamura, Shigeru Mitani, Tetsuo Yoneda
-
Publication number: 20080300261Abstract: Compounds of formula I are useful in treatment of diseases associated with the deposition of ?-amyloid in the brain.Type: ApplicationFiled: July 19, 2005Publication date: December 4, 2008Inventors: Peter Blurton, Frank Burkamp, Ian Churcher, Timothy Harrison, Joseph Neduvelil
-
Publication number: 20080274891Abstract: Compounds of the formula I in which the substituents are as defined in claim 1 are suitable for use as herbicides.Type: ApplicationFiled: May 23, 2008Publication date: November 6, 2008Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Andrew Edmunds, Alain De Mesmaeker, Christoph Luthy, Jurgen Schaetzer
-
Publication number: 20080262230Abstract: Disclosed is a novel benzyloxypropylamine derivative having an excellent tachykinin receptor antagonistic effect. This compound shows a good transfer into the blood and a long blood half-life in the blood kinetic test using a guinea pig orally administered with the compound and is stable in an animal plasma. The compound also shows a high transfer to the central nervous system when it is orally administered to a guinea pig at a certain dose. Accordingly, the benzyloxypropylamine derivative is quite useful as a novel anti-tachykinin agent.Type: ApplicationFiled: March 29, 2006Publication date: October 23, 2008Applicant: Nippon Zoki Pharmaceutical Co., LTD.Inventors: Kunihiko Higashiura, Takashi Ogino, Kazuhito Furukawa
-
Publication number: 20080246002Abstract: Compounds that are useful in compositions for flat panel displays, for example, are provided. The compounds provided are polar, and are useful in low threshold voltage mixtures. The compounds provided have the general structure: CpCOCH2[A]nZ1[B]mZ2PhX1X2Y, where CpCOCH2 is the structure: A and B are independently in each instance selected from the group consisting of 1,4-cyclohexane, 1,4-phenyl, 1,3-dioxan-5,2-diyl; pyridine-5,2-diyl; and pyrimidin-5,2-diyl; n and m are independently in each instance 0, 1 or 2; Z1 and Z2 are independently a single bond, —(CH2)2—, CF2O, OCF2, CH2O, OCH2, —C?C—, COO, OOC; and Y is selected from the group consisting of: F, Cl, CN, OCH2F, CHF2, OCF3, and CF3.Type: ApplicationFiled: April 3, 2007Publication date: October 9, 2008Inventor: Xinhua Chen
-
Publication number: 20080153823Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.Type: ApplicationFiled: December 13, 2007Publication date: June 26, 2008Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley
-
Patent number: 7378425Abstract: The present invention provides an excellent sigma receptor binding agent and/or acetylcholinesterase inhibitor containing an (1-indanone)-(1,2,3,6-tetrahydropyridine) compound. More specifically, it provides an (1-indanone)-(1,2,3,6-tetrahydropyridine) compound represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: In the formula (I), R1, R2, R3 and R4 are the same as or different from each other.Type: GrantFiled: September 15, 2004Date of Patent: May 27, 2008Assignee: Eisai R & D Management Co., Ltd.Inventors: Yoichi Iimura, Takashi Kosasa, Yoshiharu Yamanishi
-
Patent number: RE40703Abstract: The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.Type: GrantFiled: October 3, 2006Date of Patent: April 28, 2009Assignee: Schering AktiengesellschaftInventors: Tsuneji Suzuki, Tomoyuki Ando, Katsutoshi Tsuchiya, Osamu Nakanishi, Akiko Saito, Takashi Yamashita, Yoshinori Shiraishi, Eishi Tanaka